Tufton Capital Management Sells 375 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Tufton Capital Management lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 27.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 993 shares of the medical equipment provider’s stock after selling 375 shares during the period. Tufton Capital Management’s holdings in Intuitive Surgical were worth $335,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. RB Capital Management LLC lifted its holdings in shares of Intuitive Surgical by 4.4% in the first quarter. RB Capital Management LLC now owns 1,735 shares of the medical equipment provider’s stock valued at $523,000 after purchasing an additional 73 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Intuitive Surgical by 0.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 946,709 shares of the medical equipment provider’s stock valued at $285,603,000 after purchasing an additional 5,233 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Intuitive Surgical by 2.3% in the first quarter. Baird Financial Group Inc. now owns 21,089 shares of the medical equipment provider’s stock valued at $6,362,000 after purchasing an additional 481 shares in the last quarter. Brown Brothers Harriman & Co. lifted its holdings in shares of Intuitive Surgical by 576.7% in the first quarter. Brown Brothers Harriman & Co. now owns 406 shares of the medical equipment provider’s stock valued at $122,000 after purchasing an additional 346 shares in the last quarter. Finally, Covestor Ltd lifted its holdings in shares of Intuitive Surgical by 50.4% in the first quarter. Covestor Ltd now owns 418 shares of the medical equipment provider’s stock valued at $126,000 after purchasing an additional 140 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ISRG shares. Raymond James raised their target price on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. Mizuho increased their price target on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Wells Fargo & Company raised their target price on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research report on Friday, January 19th. Stifel Nicolaus raised their target price on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Finally, Truist Financial raised their target price on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $375.70.

Insiders Place Their Bets

In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Gary S. Guthart sold 24,325 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the completion of the transaction, the chief executive officer now owns 9,425 shares of the company’s stock, valued at approximately $3,544,365.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now directly owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 248,418 shares of company stock worth $95,927,097. 0.90% of the stock is currently owned by company insiders.

Intuitive Surgical Stock Performance

ISRG stock traded down $0.71 during trading on Thursday, hitting $373.46. 663,362 shares of the company traded hands, compared to its average volume of 1,621,944. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $403.76. The company has a 50-day moving average of $387.56 and a 200-day moving average of $342.39. The firm has a market capitalization of $132.37 billion, a PE ratio of 74.39, a P/E/G ratio of 5.88 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.48 by $0.12. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The business had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.89 billion. During the same quarter last year, the business posted $0.91 EPS. The business’s revenue was up 16.6% on a year-over-year basis. Sell-side analysts expect that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.